Literature DB >> 6287930

Effect of ketoconazole on isolated mitochondria from Candida albicans.

M L Shigematsu, J Uno, T Arai.   

Abstract

Ketoconazole, an oral antimycotic imidazole drug, blocked the transport of electrons in the respiratory chain of Candida albicans under aerobic conditions with different substrates, such as NADH and succinate. This effect was a nonspecific inhibition of NADH oxidases and succinate oxidases. The addition of ketoconazole to C. albicans mitochondria without a substrate resulted in strong reduction of cytochrome a3, as revealed by difference spectra (reduced versus oxidized). This indicated that there was a specific interaction between ketoconazole and cytochrome c oxidase. A spectrophotometric analysis confirmed that the cytochrome oxidases other than cytochrome c oxidase were not inhibited because subsequent addition of any substrate caused an increased level of reduction of all of the other respiratory chain components compared with the control. Consequently, our data strongly suggested that the primary site of ketoconazole inhibition on isolated mitochondria from C. albicans is the most distal portion of the respiratory chain.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6287930      PMCID: PMC182046          DOI: 10.1128/AAC.21.6.919

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Cyanide-insensitive respiration. An alternative mitochondrial pathway.

Authors:  M F Henry; E D Nyns
Journal:  Subcell Biochem       Date:  1975-03

2.  Biochemistry of dystrophic muscle. Mitochondrial succinate-tetrazolium reductase and adenosine triphosphatase.

Authors:  R J PENNINGTON
Journal:  Biochem J       Date:  1961-09       Impact factor: 3.857

3.  The alternate respiratory pathway of Candida albicans.

Authors:  M G Shepherd; C M Chin; P A Sullivan
Journal:  Arch Microbiol       Date:  1978-01-23       Impact factor: 2.552

4.  Evidence for the occurrence in submitochondrial particles of a dual respiratory chain containing different forms of cytochrome b.

Authors:  B Norling; B D Nelson; K Nordenbrand; L Ernster
Journal:  Biochim Biophys Acta       Date:  1972-07-12

5.  Heterogeneity of action of mechanisms among antimycotic imidazoles.

Authors:  I J Sud; D S Feingold
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

6.  Ketoconazole: a new drug for the treatment of paracoccidioidomycosis.

Authors:  A Restrepo; D A Stevens; I Gómez; E Leiderman; R Angel; J Fuentes; A Arana; G Mejía; A C Vanegas; M Robledo
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

7.  Chronic mucocutaneous candidosis and other superficial and systemic mycoses successfully treated with ketoconazole.

Authors:  E Drouhet; B Dupont
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

8.  Suppression of cryptococcosis and histoplasmosis by ketoconazole in athymic nude mice.

Authors:  D M Williams; J R Graybill; D J Drutz; H B Levine
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

9.  Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400.

Authors:  D Dixon; S Shadomy; H J Shadomy; A Espinel-Ingroff; T M Kerkering
Journal:  J Infect Dis       Date:  1978-08       Impact factor: 5.226

10.  Oral therapy for experimental coccidioidomycosis with R41 400 (ketoconazole), a new imidazole.

Authors:  H B Levine; J M Cobb
Journal:  Am Rev Respir Dis       Date:  1978-10
View more
  12 in total

1.  Evaluation of antifungal activity of antimycotics by automatic analyzing system.

Authors:  K Oh; H Matsuoka; O Sumita; K Takatori; H Kurata
Journal:  Mycopathologia       Date:  1992-05       Impact factor: 2.574

2.  Azole susceptibility and hyphal formation in a cytochrome P-450-deficient mutant of Candida albicans.

Authors:  N D Lees; M C Broughton; D Sanglard; M Bard
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  Sensitivity testing with ketoconazole in an assay containing Candida albicans, human polymorphonuclear leukocytes and serum.

Authors:  T M Bauer; W Kronsteiner; M Bassler; F D Daschner
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

Review 4.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

Review 5.  Use of amphotericin B with azole antifungal drugs: what are we doing?

Authors:  A M Sugar
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

6.  Relationships between respiration and susceptibility to azole antifungals in Candida glabrata.

Authors:  Sophie Brun; Christophe Aubry; Osana Lima; Robert Filmon; Thierry Bergès; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

7.  Mechanisms of azole resistance in petite mutants of Candida glabrata.

Authors:  Sophie Brun; Thierry Bergès; Pascal Poupard; Carole Vauzelle-Moreau; Gilles Renier; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi.

Authors:  C Borelli; M Schaller; M Niewerth; K Nocker; B Baasner; D Berg; R Tiemann; K Tietjen; B Fugmann; S Lang-Fugmann; H C Korting
Journal:  Chemotherapy       Date:  2008-06-30       Impact factor: 2.544

Review 9.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

10.  Novel synergism of two antifungal agents, copiamycin and imidazole.

Authors:  J Uno; M L Shigematsu; T Arai
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.